This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Jun;20(6):344.

doi: 10.1038/s41575-023-00785-0.

Zolbetuximab treatment in metastatic gastric cancer

Eleni Kotsiliti¹

Affiliations

PMID: 37085616
DOI: 10.1038/s41575-023-00785-0

Comment

Zolbetuximab treatment in metastatic gastric cancer

Eleni Kotsiliti. Nat Rev Gastroenterol Hepatol. 2023 Jun.

. 2023 Jun;20(6):344.

doi: 10.1038/s41575-023-00785-0.

Author

Eleni Kotsiliti¹

Affiliation

¹ Nature Reviews Gastroenterology & Hepatology, . nrgasthep@nature.com.

PMID: 37085616
DOI: 10.1038/s41575-023-00785-0

No abstract available

PubMed Disclaimer

Comment on

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.

References

1. Lancet. 2023 May 20;401(10389):1655-1668 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information